## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($128.01)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Neurocrine Biosciences (NBIX) Valuation Check After KINECT DCP Phase 3 Trial Failure**
- Source: Simply Wall Street | 20260104T210930 | Somewhat-Bearish | Relevance: 100%
- Neurocrine Biosciences (NBIX) shares are under pressure after its Phase 3 KINECT DCP trial for dyskinetic cerebral palsy failed to meet primary and secondary endpoints. Despite recent stock declines, the company remains profitable, and analysts suggest it may be undervalued, trading at a discount to targets. However, its high P/E ratio compared to the biotech sector indicates that investors might be paying a premium for future growth.

**2. Merit Financial Group LLC Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20260104T100930 | Somewhat-Bullish | Relevance: 100%
- Merit Financial Group LLC significantly increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 101.3% in Q3, now holding 14,626 shares valued at $2.05 million. This comes despite recent insider selling, totaling $6.57 million in the last 90 days. Neurocrine Biosciences reported strong Q3 earnings, exceeding expectations with $2.17 EPS and $794.9 million in revenue, contributing to a "Moderate Buy" consensus rating and an average price target of $175.25 from analysts.

**3. Braun Stacey Associates Inc. Has $25.69 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20260103T040930 | Bullish | Relevance: 100%
- Braun Stacey Associates Inc. significantly increased its stake in Neurocrine Biosciences, Inc. by 7.4% in the third quarter, holding 183,027 shares valued at $25.69 million. This move comes as Neurocrine Biosciences reported strong Q3 earnings, exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating with an average price target of $175.25. Despite recent insider selling, institutional ownership remains high at 92.59%.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | HC Wainwright & | $198 | $168 | +18% |
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | HC Wainwright & | main | Buy |
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 10 ($2.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Near-term weakness: 7.3% below SMA50 despite long-term uptrend.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +13%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 14.8x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (4 raises, avg +13%, $186 target (+36%)). Insider selling cluster ($3.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.6B |
| Beta | 0.28 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 14.8 |
| Current P/E | 19.7 |
| YoY Growth | 32.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.5% to -5.1% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.1pp (needs >3.0% for momentum thesis). Underperforming sector by 5.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). MACD histogram bearish (-1.35), momentum weakening. OFD pattern: -DBH (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.10% (CS: 2) | Weak |
| RSI_14 | 32.1 | Neutral |
| MACD Histogram | -1.35 | Bearish |
| vs SMA20 | 0.922x | Below |
| vs SMA50 | 0.927x | Below |
| vs SMA200 | 1.037x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $135.99
- **Stop Loss:** $128.01 (5.9% risk)
- **Target:** $143.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 108
- **Position Value:** $14,686.92
- **Portfolio %:** 14.69%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*